NImmune Secures Rights to Omilancor for Asian Market

NImmune Biopharma, a private biopharmaceutical company specializing in precision treatments for inflammation and immunology (I&I), has secured exclusive rights to develop and commercialize omilancor in Asia. This deal covers major markets such as China, Hong Kong, Taiwan, South Korea, and several Southeast Asian nations including Thailand, Singapore, and Vietnam.

With this acquisition, NImmune will gain full global control over omilancor, along with its entire LANCL2 immunoregulatory portfolio. Omilancor, a once-daily oral therapy currently in Phase 3 trials for ulcerative colitis and Phase 2 for Crohn’s disease, is positioned as a best- and first-in-class treatment for multiple I&I conditions.

Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune, said in a statement, “The wind-down of LianBio, announced on February 13, 2024, provided an unprecedented opportunity to consolidate global rights to omilancor in NImmune and capture significant additional value for shareholders. We are very excited to continue late-stage development of omilancor and bring the best- and first-in-class potential of an oral therapeutic to patients with ulcerative colitis and Crohn’s disease.”

He further continued, “The timing of this transaction could not have been more ideal as we launch the global Phase 3 program of omilancor in UC. We now look forward to completing ongoing discussions with potential global and regional strategic partners that can help to further accelerate Phase 3 timelines and bring the best-in-class potential of omilancor to address the unmet needs of millions of IBD patients in the U.S. and worldwide.”